Toronto Dominion Bank
VKTX icon

Toronto Dominion Bank’s Viking Therapeutics VKTX Stock Holding History

Toronto Dominion Bank’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-693
Closed -$2K – 1914
2022
Q1 		$2K Buy
+693
New +$2.49K ﹤0.01% 1316

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Toronto Dominion Bank's VKTX Position: Q2 2022 in Review

Toronto Dominion Bank sold out of Viking Therapeutics (VKTX) in Q2 2022, closing a stake of 693 shares — an estimated $2K sold.

Toronto Dominion Bank first reported a position in VKTX in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 114 funds tracked by Wall St. Rank hold VKTX as of Q2 2022.

  • Toronto Dominion Bank reported no remaining Viking Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Toronto Dominion Bank sold 693 Viking Therapeutics shares in Q2 2022, an estimated $2K.
  • Toronto Dominion Bank first reported a position in Viking Therapeutics in Q1 2022 and held it in 1 quarter.
  • Toronto Dominion Bank's Viking Therapeutics position peaked at $2K in Q1 2022.
  • 114 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2022.

Based on Toronto Dominion Bank's 13F filing for Q2 2022, filed 11 Aug 2022.